Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson Syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis

Tangamornsuksan, Wimonchat, Chaiyakunapruk, Nathorn, Somkrua, Ratchadaporn, Lohitnavy, Manupat and Tassaneeyakul, Wichittra (2013) Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson Syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. Jama Dermatology, 149 9: 1025-1032. doi:10.1001/jamadermatol.2013.4114

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ314087_OA.pdf Full text (open access) application/pdf 261KB 0

Author Tangamornsuksan, Wimonchat
Chaiyakunapruk, Nathorn
Somkrua, Ratchadaporn
Lohitnavy, Manupat
Tassaneeyakul, Wichittra
Title Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson Syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis
Formatted title
Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson Syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis
Journal name Jama Dermatology   Check publisher's open access policy
ISSN 2168-6068
2168-6084
Publication date 2013-09-01
Year available 2013
Sub-type Article (original research)
DOI 10.1001/jamadermatol.2013.4114
Open Access Status File (Publisher version)
Volume 149
Issue 9
Start page 1025
End page 1032
Total pages 8
Place of publication Chicago, IL, United States
Publisher American Medical Association
Language eng
Formatted abstract
Importance The US Food and Drug Administration recommends screening for the HLA-B*1502 allele before initiation of carbamazepine therapy in patients of Asian ancestry, but there remains unclear evidence of a relationship between HLA-B*1502 and Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) among carbamazepine users, especially in some racial/ethnic populations.

Objective To determine the relationship between the HLA-B*1502 allele and carbamazepine-induced SJS and TEN.

Data Sources A comprehensive search of the following data sources was performed without language restriction from the inception of the database until January 8, 2013: EMBASE, PubMed, clinicaltrials.gov, Cochrane Library, IPA (International Pharmaceutical Abstracts), HuGENet (Human Genome Epidemiology Network), and CINAHL (Cumulative Index to Nursing and Allied Health Literature), and the reference lists of identified studies.

Study Selection Inclusion criteria were studies that investigated the relationship between HLA-B*1502 and carbamazepine-induced SJS and TEN and that reported sufficient data for calculating the frequency of HLA-B*1502 carriers among cases and controls. The search yielded 525 articles, of which 16 met the inclusion criteria. The studies included 227 SJS or TEN cases, 602 matched control subjects, and 2949 population control subjects.

Data Extraction and Synthesis Two reviewers independently extracted the following data: study design, eligibility criteria, diagnostic criteria, patient demographics, genotype distribution, HLA-B genotyping technique, selection of cases and controls, dosage of carbamazepine and duration of use, and results of Hardy-Weinberg equilibrium in the control group. The Newcastle-Ottawa Scale was used to assess the quality of studies. The overall odds ratios (ORs) with corresponding 95% CIs were calculated using a random-effects model. The primary analysis was based on matched control studies. Subgroup analyses by race/ethnicity were also performed.

Main Outcome and Measure The primary outcome was carbamazepine-induced SJS and TEN. The outcome measure is given as an overall OR.

Results The summary OR for the relationship between HLA-B*1502 and carbamazepine-induced SJS and TEN was 79.84 (95% CI, 28.45-224.06). Racial/ethnic subgroup analyses yielded similar findings for Han-Chinese (115.32; 18.17-732.13), Thais (54.43; 16.28-181.96), and Malaysians (221.00; 3.85-12 694.65). Among individuals of white or Japanese race/ethnicity, no patients with SJS or TEN were carriers of the HLA-B*1502 allele.

Conclusions and Relevance We found a strong relationship between the HLA-B*1502 allele and carbamazepine-induced SJS and TEN in Han-Chinese, Thai, and Malaysian populations. HLA-B*1502 screening in patients requiring carbamazepine therapy is warranted.
Keyword Adverse drug reactions
Induced hypersensitivity reactions
Major histocompatibility complex
HLA-B locus
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2014 Collection
School of Public Health Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 48 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 58 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 10 Nov 2013, 10:46:50 EST by System User on behalf of School of Public Health